Entecavir as prophylaxis against hepatitis B virus reactivation following chemotherapy for lymphoma

被引：11
作者：
Uchiyama, Michihiro [1 ]
Tamai, Yotaro [1 ]
Ikeda, Takashi [1 ]
机构：
[1] Shizuoka Canc Ctr, Div Hematol & Stem Cell Transplantat, Nagaizumi, Shizuoka 4118777, Japan
来源：
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES | 2010年 / 14卷 / 03期
关键词：
LAMIVUDINE THERAPY;
D O I：
10.1016/j.ijid.2009.04.014
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：E265 / E266
页数：2
相关论文
共 11 条
[1]   A dose-ranging study of the efficacy and tolerability of entecavir in lamivudine-refractory chronic hepatitis B patients [J].
Chang, TT ;
Gish, RG ;
Hadziyannis, SJ ;
Cianciara, J ;
Rizzetto, M ;
Schiff, ER ;
Pastore, G ;
Bacon, BR ;
Poynard, T ;
Joshi, S ;
Klesczewski, KS ;
Thiry, A ;
Rose, RE ;
Colonno, RJ ;
Hindes, RG .
GASTROENTEROLOGY, 2005, 129 (04) :1198-1209
[2]  
COLONNO RJ, 2007, 42 ANN M EUR ASS STU, P781
[3]  
KOBASHI H, 2007, 58 ANN M AM ASS STUD, P963
[4]   Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B [J].
Lai, CL ;
Dienstag, J ;
Schiff, E ;
Leung, NWY ;
Atkins, M ;
Hunt, C ;
Brown, N ;
Woessner, M ;
Boehme, R ;
Condreay, L .
CLINICAL INFECTIOUS DISEASES, 2003, 36 (06) :687-696
[5]   Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy [J].
Lau, GKK ;
Yiu, HHY ;
Fong, DYT ;
Cheng, HC ;
Au, WY ;
Lai, LSF ;
Cheung, M ;
Zhang, HY ;
Lie, A ;
Ngan, R ;
Liang, R .
GASTROENTEROLOGY, 2003, 125 (06) :1742-1749
[6]   Clinical experience with lamivudine [J].
Leung, N .
SEMINARS IN LIVER DISEASE, 2002, 22 :15-21
[7]   Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma [J].
Li, YH ;
He, YF ;
Jiang, WQ ;
Wang, FH ;
Lin, XB ;
Zhang, L ;
Xia, ZJ ;
Sun, XF ;
Huang, HQ ;
Lin, TY ;
He, YJ ;
Guan, ZZ .
CANCER, 2006, 106 (06) :1320-1325
[8]  
Liaw YF, 2004, ANTIVIR THER, V9, P257
[9]   The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance [J].
Ono, SK ;
Kato, N ;
Shiratori, Y ;
Kato, J ;
Goto, T ;
Schinazi, RF ;
Carrilho, FJ ;
Omata, M .
JOURNAL OF CLINICAL INVESTIGATION, 2001, 107 (04) :449-455
[10]   Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers [J].
Shibolet, O ;
Ilan, Y ;
Gillis, S ;
Hubert, A ;
Shouval, D ;
Safadi, R .
BLOOD, 2002, 100 (02) :391-396
12